Physician profile
Robert P Camara
NPI 1942207931
$195.31
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $65.02 | 2019 | |
| Novo Nordisk INC | $26.86 | 2019 | |
| Janssen Pharmaceuticals, INC | $23.61 | 2019 | |
| Astellas Pharma US INC | $17.47 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.66 | 2019 | |
| Amgen INC. | $13.08 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.11 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.29 | 2019 | |
| Merck Sharp & Dohme LLC | $11.21 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Camara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.